Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Connect Biopharma Holdings Ltd ADR (NQ: CNTB ) 1.151 -0.099 (-7.89%) Streaming Delayed Price Updated: 11:04 AM EDT, Oct 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 20,250 Open 1.200 Bid (Size) 1.150 (10) Ask (Size) 1.170 (1) Prev. Close 1.250 Today's Range 1.151 - 1.200 52wk Range 0.6777 - 2.840 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Attovia Therapeutics Appoints Chief Financial Officer October 15, 2024 Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer From Attovia Therapeutics, Inc. Via GlobeNewswire Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024 September 10, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Performance YTD -6.39% -6.39% 1 Month -6.39% -6.39% 3 Month -10.05% -10.05% 6 Month -14.71% -14.71% 1 Year +11.78% +11.78% More News Read More Week In Review: EpimAb Sells T-Cell Engager In $635 Million Deal September 07, 2024 Via Talk Markets Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update September 05, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum July 01, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Pre-Market Session June 13, 2024 Via Benzinga Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) June 12, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Announces New Leadership and Chair of the Board of Directors June 12, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma May 22, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma May 07, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update April 16, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session April 03, 2024 Via Benzinga Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference March 19, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 20, 2024 Via Benzinga Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors February 12, 2024 From Connect Biopharma Holdings Limited Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Pre-Market Session February 02, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session January 23, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session December 29, 2023 Via Benzinga Week in Review: SystImmune Out-Licenses Global Rights for ADC to BMS in $8.4 Billion Deal December 16, 2023 Via Talk Markets Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket December 12, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday December 12, 2023 Via InvestorPlace Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma December 12, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session December 11, 2023 Via Benzinga Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023 December 11, 2023 From Connect Biopharma Holdings Limited Via GlobeNewswire Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management November 30, 2023 Via Newsfile Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
